Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.

International journal of cancer - 20 Mar 2002

Jäger Elke, Höhn Hauni, Necker Artje, Förster Reinhold, Karbach Julia, Freitag Kirsten, Neukirch Claudia, Castelli Chiara, Salter Russell D, Knuth Alaxander, Maeurer Markus J

Abstract excerpt

Monitoring of CD8+ T-cell responses in cancer patients during peptide vaccination is essential to provide useful surrogate markers and to demonstrate vaccine efficacy. We have longitudinally followed CD8+ T-cell responses in 3 melanoma patients who were immunized with peptides derived from Melan-A/MART-1. Recombinant HLA-A2 tetramers loaded with the naturally presented Melan-A/MART-1 nonamer peptide (AAGIGILTV)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Complementarity Determining Regions

Share to HLA-A2 Antigen

Share to Oligopeptides

Share to Receptors, Antigen, T-Cell

Share to Vaccination

Share to Vaccines, Subunit

Source

Identifiers

PMID: 11920589
DOI: 10.1002/ijc.10165

Genes

CCR7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.PMID 11920589Read ↗

Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.Semantic proximity Read ↗

Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.Semantic proximity Read ↗

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patientsSemantic proximity Read ↗

Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma Peptide vaccine.Semantic proximity Read ↗

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.Semantic proximity Read ↗

Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.Semantic proximity Read ↗

Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.Semantic proximity Read ↗

Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex.Semantic proximity Read ↗

Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.Semantic proximity Read ↗

Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.Semantic proximity Read ↗

Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.Semantic proximity Read ↗

Melanoma antigens recognised by CD8+ and CD4+ T cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.